Functional characterization of α1-adrenoceptor subtypes in longitudinal and circular muscle of human vas deferens

被引:16
作者
Amobi, N
Guillebaud, J
Coker, C
Mulvin, D
Smith, ICH
机构
[1] Univ London Kings Coll, Div Biomed Sci, London W8 7AH, England
[2] Margaret Pyke Ctr, London W1, England
[3] Univ London Kings Coll Hosp, Dept Urol, London SE5, England
基金
英国惠康基金;
关键词
vas deferens; human; noradrenaline; alpha(1)-adrenoceptor subtype;
D O I
10.1016/S0014-2999(98)00989-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The alpha(1)-adrenoceptor subtype(s) mediating contraction to noradrenaline in longitudinal and circular muscle of human epididymal vas deferens was studied using competitive antagonists. The effects of the alkylating agents, phenoxybenzamine and chloroethylclonidine were also investigated. Noradrenaline evoked concentration-dependent contractions of longitudinal and circular muscle with comparable potencies (pD(2); 5.6 and 5.5 respectively). The contractions in longitudinal and circular muscle respectively were inhibited by prazosin (pA(2), 8.6 and pK(B), 9.2), 5-methylurapidil (pK(B), 8.7 and 9.1) and less potently by spiperone (pA(2), 7.1) or BMY 7378 (pK(B), 6.3 and 6.6). Contractions of the circular but not longitudinal muscle was comparatively insensitive to pretreatment with phenoxybenzamine. In contrast pretreatment with chloroethylclonidine reduced the contractions in both muscle types and also enhanced phenoxybenzamine-sensitivity in longitudinal but not circular muscle. The results suggest that contractions evoked by noradrenaline in both muscle types of human vas deferens is mediated via activation of alpha(1)-adrenoceptors with pharmacological profile of the alpha(1A)-subtype. However the involvement of alpha(1A)-adrenoceptor variants, such as the hypothesised alpha(1L)-subtype may underlie the differential effects of phenoxybenzamine in longitudinal and circular muscle. Factors contributing to chloroethylclonidine-sensitivity are discussed. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 42 条
[11]   The effects of SB 216469, an antagonist which discriminates between the alpha(1A)-adrenoceptor and the human prostatic alpha(1)-adrenoceptor [J].
ChessWilliams, R ;
Chapple, CR ;
Verfurth, F ;
Noble, AJ ;
Couldwell, CJ ;
Michel, MC .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (06) :1093-1100
[12]   Unusual alpha-adrenoceptor subtype in canine saphenous vein: Comparison to mesenteric vein [J].
Daniel, EE ;
Low, AM ;
Gaspar, V ;
LuChao, H ;
Green, J ;
Akrong, J ;
Duerksen, S ;
Soyka, C ;
Chen, CK ;
Boyd, J ;
Kwan, CY .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (07) :1535-1543
[13]   Characterization of alpha(1D)-adrenoceptor subtype in rat myocardium, aorta and other tissues [J].
Deng, XF ;
Chemtob, S ;
Varma, DR .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (02) :269-276
[14]  
ESBENSHADE TA, 1993, PHARM COMMUN, V3, P323
[15]   ALPHA-1-ADRENOCEPTOR CLASSIFICATION - SHARPENING OCCAM RAZOR [J].
FORD, APDW ;
WILLIAMS, TJ ;
BLUE, DR ;
CLARKE, DE .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (06) :167-170
[16]   Pharmacological pleiotropism of the human recombinant alpha(1A)-adrenoceptor: implications for alpha(1)-adrenoceptor classification [J].
Ford, APDW ;
Daniels, DV ;
Chang, DJ ;
Gever, JR ;
Jasper, JR ;
Lesnick, JD ;
Clarke, DE .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (06) :1127-1135
[17]  
FORRAY C, 1994, MOL PHARMACOL, V45, P703
[18]   ALPHA(1A)-ADRENOCEPTOR-MEDIATED CONTRACTILE RESPONSES OF THE HUMAN VAS-DEFERENS [J].
FURUKAWA, K ;
ROSARIO, DJ ;
SMITH, DJ ;
CHAPPLE, CR ;
UCHIYAMA, T ;
CHESSWILLIAMS, R .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (01) :1605-1610
[19]   ALPHA-1-ADRENOCEPTOR SUBTYPES LINKED TO DIFFERENT MECHANISMS FOR INCREASING INTRACELLULAR CA-2+ IN SMOOTH-MUSCLE [J].
HAN, C ;
ABEL, PW ;
MINNEMAN, KP .
NATURE, 1987, 329 (6137) :333-335
[20]   PHARMACOLOGICAL EVIDENCE OF DISTINCT ALPHA(1)-ADRENOCEPTOR SUBTYPES MEDIATING THE CONTRACTION OF HUMAN PROSTATIC URETHRA AND PERIPHERAL ARTERY [J].
HATANO, A ;
TAKAHASHI, H ;
TAMAKI, M ;
KOMEYAMA, T ;
KOIZUMI, T ;
TAKEDA, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (03) :723-728